PT-141 (Bremelanotide) research guide for Sződ. Melanocortin-4 receptor agonist studied for sexual function — covers purity standards, COA testing, and sourcing.
Research-Grade PT-141 (Bremelanotide) for Sződ Investigators
Most researchers trying to source PT-141 (Bremelanotide) in Sződ immediately realize that local retail options are essentially nonexistent. This concentration of supply in online vendors is a genuine benefit for researchers — top vendors differentiate through analytical documentation in ways brick-and-mortar outlets simply cannot. Separating quality PT-141 (Bremelanotide) from the rest of the market depends on three things: an HPLC chromatogram showing ≥98% purity, mass spec data confirming the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Sződ researchers need to know about purchasing, testing, and working with PT-141 (Bremelanotide) for scientific research use.
The Science Behind PT-141 (Bremelanotide)
The melanocortin receptor family (MC1R through MC5R) mediates a diverse range of physiological functions, and research peptides like Melanotan-2 and PT-141 (Bremelanotide) act on different receptor subtypes with different research applications. MT-2 has broad melanocortin receptor activity and has been studied for pigmentation (MC1R), appetite suppression (MC4R), and other endpoints. PT-141 is a more specific MC3R/MC4R agonist studied primarily for CNS-mediated effects. For researchers in Sződ designing experiments with PT-141 (Bremelanotide), the specific receptor binding profile determines which outcomes are mechanistically attributable to the compound and which require additional explanation.
PT-141 (Bremelanotide) Purchasing Guide
The first step for any Sződ researcher sourcing PT-141 (Bremelanotide) is locating suppliers that experienced researchers actively recommend — search results alone are too heavily influenced by marketing spend. A COA for PT-141 (Bremelanotide) should include: HPLC purity percentage with the underlying chromatogram, mass spectrometry data verifying the correct molecular weight, endotoxin test results, and a residual solvent panel — all specific to the lot you receive. Strong quality indicators beyond COA quality: established track record of at least two years, knowledgeable support capable of explaining COA data, and cold chain packaging that protects product integrity. Store lyophilised PT-141 (Bremelanotide) at minus 20 degrees Celsius until ready to use; reconstitute only the quantity required for your immediate research and keep the remainder frozen.
Order PT-141 (Bremelanotide) — ships to Sződ
COA-verified · International tracking · Research grade
PT-141 (Bremelanotide) Safety, Handling & Research Protocols
PT-141 (Bremelanotide) is available for research use only and is not approved for human consumption by the FDA or comparable health authorities — all information here is educational. Lyophilised PT-141 (Bremelanotide) should be stored frozen (−20°C) immediately upon receipt; avoid repeatedly thawing and refreezing reconstituted peptide by dividing into single-dose aliquots before freezing. The primary quality-related safety risk in PT-141 (Bremelanotide) research is endotoxin from inadequately tested product — a documented endotoxin result in your specific batch certificate is the key safeguard. Protocol documentation — documenting product details, dates, and administration precisely — is a research best practice for PT-141 (Bremelanotide) that makes anomalous results interpretable.
Frequently Asked Questions
What is the regulatory status of PT-141?
PT-141 (as Bremelanotide/Vyleesi) is an FDA-approved pharmaceutical in the US for HSDD in premenopausal women. This pharmaceutical status means it is more tightly regulated than pure research compounds in most jurisdictions. Import and possession regulations vary by country — verify current status in your jurisdiction before ordering.
What is PT-141?
PT-141 (Bremelanotide) is a cyclic melanocortin receptor agonist developed from Melanotan-2. Unlike MT-2, PT-141 acts primarily on MC3R and MC4R receptors in the CNS rather than MC1R in melanocytes. It received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. As a research compound it is studied for melanocortin receptor pharmacology.
How does PT-141 differ from Melanotan-2?
Both are melanocortin receptor agonists, but PT-141 is more selective for MC3R/MC4R (CNS-expressed receptors) while MT-2 has broader activity including MC1R (melanocytes) for pigmentation. PT-141 was specifically developed from MT-2 to have the CNS effects with reduced pigmentation side effects.
